Most cells rely on a system called homologous recombination or HR, which uses proteins called BRCA1 and BRCA2 for accurate DNA repair. Those born with a malfunctioning BRCA gene, however, often develop breast and ovarian cancers, with BRCA mutations and related HR problems recently found to occur in pancreatic and prostate cancer as well.
For this reason, identifying patients with "HR-deficient" cancers has become a priority in the field, in part because such cancer cells are vulnerable to targeted therapies that break their DNA. To find patients with HR deficiency, standard lab tests look for "scars" in the DNA of cancer cells, which happen when sloppy, back-up repair processes are used instead of HR to create specific mutation patterns.
While accurate scar diagnosis enables more tailored treatment, researchers have been puzzled by the subtly of the scars found in HR-deficient cancers. Such scars create very small typos in the DNA code (sequence), which are invisible under the microscope. However, HR-deficient cells show dramatic structural rearrangements in much larger DNA structures called chromosomes that are visible by microscopy.
To tackle this paradox, Marcin Imieliński, MD, PhD, at NYU Langone Health’s Perlmutter Cancer Center, and Simon Powell, MD, PhD, at Memorial Sloan Kettering Cancer Center (MSKCC), applied “genome graph” techniques developed in Imieliński’s lab to detect massive structural DNA changes that rearrange, copy, and delete huge sections of chromosomes. Published online August 16 in the journal Nature, their study also analyzed DNA molecules a hundred times longer than those normally measured in cancer analyses.
Applying these methods, the research team identified "reciprocal pairs," a new scar type seen in HR deficiency. By analyzing thousands of cancer genomes, the research team showed that when HR fails, reciprocal pair scars create specific chromosomal changes visible by microscope and that better explain the biology of HR-deficient cells.
"The long molecules tell us that these scars come from two backup repair mechanisms - homology-independent replication restart and single strand annealing - that may keep HR-deficient cancer cells alive," says Imieliński, director of Cancer Genomics at Perlmutter Cancer Center, and an attending pathologist at NYU Langone. "Blocking the mechanisms may represent new ways to treat these cancers."
The study authors note that their new techniques require the use of a technology called whole genome sequencing (WGS), but that WGS costs are falling. The researchers say it may soon be practical to use their approach to find more HR-deficient patients and match them with targeted therapies.
Setton J, Hadi K, Choo ZN, Kuchin KS, Tian H, Da Cruz Paula A, Rosiene J, Selenica P, Behr J, Yao X, Deshpande A, Sigouros M, Manohar J, Nauseef JT, Mosquera JM, Elemento O, Weigelt B, Riaz N, Reis-Filho JS, Powell SN, Imieliński M.
Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.
Nature. 2023 Aug 16. doi: 10.1038/s41586-023-06461-2